Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial

William HK Schilling, Podjanee Jittamala, James A Watson, Simon Boyd, Viravarn Luvira, Tanaya Siripoon, Thundon Ngamprasertchai, Elizabeth M. Batty, Cintia Cruz, James J. Callery, Shivani Singh, Manisaree Saroj, Varaporn Kruabkontho, Thatsanun Ngernseng, Nuttakan Tanglakmankhong, Jaruwan Tubprasert, Mohammad Yazid Abdad, Wanassanan Madmanee, Jindarat Kouhathong, Kanokon Suwannasin, Watcharee Pagornrat, Nattaporn Piaraksa, Pongtorn Hanboonkunupakarn, Borimas Hanboonkunupakarn, Kittiyod Poovorawan, Manus Potaporn, Attasit Srisubat, Bootsakorn Loharjun, Walter Taylor, Vasin Chotivanich, Kesinee Chotivanich, Mallika Imwong, Sasithon Pukrittayakamee, Arjen M. Dondorp, Nicholas Day, Mauro Martins Teixeira, Watcharapong Piyaphanee, Weerapong Phumratanaprapin, Sir Nicholas White, Sir Nicholas White, William HK Schilling, Weerapong Phumratanaprapin, Viravarn Luvira, James J. Callery, Nicholas Day, Sasithon Pukrittayakamee, Simon Boyd, Cintia Cruz, Arjen M. Dondorp, Walter RJ Taylor, James A Watson, Watcharapong Piyaphanee, Kittiyod Poovorawan, Thundon Ngamprasertchai, Tanaya Siripoon, Borimas Hanboonkunupakarn, Kesinee Chotivanich, Podjanee Jittamala, Mallika Imwong, Janjira Thaipadungpanit, Maneerat Ekkapongpisit, Varaporn Kruabkontho, Thatsanun Ngernseng, Jaruwan Tubprasert, Mohammad Yazid Abdad, Elizabeth M. Batty, Shivani Singh, Vasin Chotivanich, Wiroj Ruksakul, Chunlanee Sangketchon, Pongtorn Hanboonkunupakarn, Sakol Sookprome, Mauro Martins Teixeira, Pedro J Almeida, Renato Santana Aguiar, Franciele Santos, Elizabeth A. Ashley, Manivanh Vongsouvath, Koukeo Phommasone, Audrey Dubot‐Pérès, Sisouphanh Vidhamaly, Ammala Chingsanoon, Sixiong Bisayher, Danoy Chommanam, Terry John Evans, Vayouly Vidhamaly, Latsaniphone Boutthasavong, Mayfong Mayxay, Manus Potaporn, Attasit Srisubat, Bootsakorn Loharjun (2023). Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial. The Lancet Infectious Diseases, 24(1), pp. 36-45, DOI: 10.1016/s1473-3099(23)00493-0.